Eloxx Pharmaceuticals Q3 net loss widens on higher costs
Overview
US rare kidney disease drug developer's Q3 net loss widened from prior year
Higher R&D and G&A costs drove increased quarterly loss
Outlook
Eloxx expects cash and cash equivalents to fund operations into 2028
Result Drivers
CLINICAL TRIAL SPENDING - Higher R&D expenses due to initiation of Phase 2b EXACT study and increased personnel costs
ADMINISTRATIVE COSTS - G&A expenses rose on higher professional fees, personnel, and facility costs
INTEREST INCOME - Higher interest income on increased cash balances following June 2026 public offering
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $5.54 mln | ||
Q3 Income from Operations | -$5.95 mln | ||
Q3 Loss Per Basic Share | $0.49 | ||
Q3 Operating Expenses | $5.95 mln |
Reuters Recommended Reads
Nov 13 - PDS Biotechnology Q3 net loss narrows on lower R&D costs
Nov 13 - Inhibrx Q3 net loss widens on higher G&A expenses
Nov 13 - Aardvark Therapeutics Q3 net loss widens, misses estimates
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)